



## **AMGEN**

Advancing the Science and Practice of Nephrology

Amgen (Europe) GmbH
Dammstrasse 23
CH-6300 Zug
Switzerland
www.amgen.com
© 2017 Amgen Inc. All rights reserved.





## Friday 29 September

19.30

Dinner

Friday 29 September		Saturday 30 September	
12.00–13.00 13.00–14.45	Plenary session (Chair: Pieter Evenepoel, Belgium) Welcome and introduction to Day 1 Bruno Fouqueray, Amgen Past, present and future: the continuing challenge of CKD-MBD John Cunningham, UK Overview of calcimimetics and their clinical use Jordi Bover, Spain	09.00-10.55	Plenary session (Chair: John Cunningham, UK) Introduction to Day 2 Bruno Fouqueray, Amgen  New insights into the role of FGF23 in CKD-MBD and beyond Marc Vervloet, The Netherlands  Bone strength and fracture risk: current concepts in CKD-MBD  Pieter Evenepoel, Belgium
14 45 15 15	Panel discussion Session faculty Coffee break		Potential impact of updated CKD-MBD guidelines on cardiovascular outcomes David Wheeler, UK
	Plenary session		Panel discussion
10.10-10.10	The benefit-risk profile of etelcalcetide		Session faculty
	Bruno Fouqueray, Amgen	10.55–11.20	Coffee break
	Workshop rotation 1 Delegates break into two groups and attend one of the following two workshop sessions:	11.20–12.40	Workshop rotation 2 Delegates break into two groups and attend one of the following two workshop sessions:
	Treating patients with CKD-MBD David Wheeler, UK together with Amgen	40 40 40 50	David Wheeler, UK together with Amgen  Etelcalcetide: from clinical trial data to
	Etelcalcetide: from clinical trial data to real-world experience  Marc Vervloet, The Netherlands together with Amgen		real-world experience Marc Vervloet, The Netherlands together with Amgen
18.05–18.10	Plenary session	12.40-12.50	Plenary session Closing remarks
	Day 1 summary		Bruno Fouqueray, Amgen
40.00	Bruno Fouqueray, Amgen	12.50-13.50	Lunch and departures